Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Cash from Investing Activities (2020 - 2022)

Ensysce Biosciences (ENSC) has disclosed Cash from Investing Activities for 3 consecutive years, with $4500.0 as the latest value for Q1 2022.

  • On a quarterly basis, Cash from Investing Activities rose 107.2% to $4500.0 in Q1 2022 year-over-year; TTM through Dec 2022 was $4500.0, a N/A change, with the full-year FY2022 number at $4500.0, changed N/A from a year prior.
  • Cash from Investing Activities was $4500.0 for Q1 2022 at Ensysce Biosciences, up from -$62500.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $183.4 million in Q4 2020 to a low of -$182.8 million in Q3 2020.
  • A 3-year average of $30.6 million and a median of $24.1 million in 2020 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: plummeted 100.05% in 2021, then surged 107.2% in 2022.
  • Ensysce Biosciences' Cash from Investing Activities stood at $183.4 million in 2020, then tumbled by 100.03% to -$62500.0 in 2021, then soared by 107.2% to $4500.0 in 2022.
  • Per Business Quant, the three most recent readings for ENSC's Cash from Investing Activities are $4500.0 (Q1 2022), -$62500.0 (Q1 2021), and $183.4 million (Q4 2020).